Systematic determination of the packaging limit of lentiviral vectors
- PMID: 11589831
- DOI: 10.1089/104303401753153947
Systematic determination of the packaging limit of lentiviral vectors
Abstract
Because of their ability to transduce nondividing cells, human immunodeficiency virus type 1 (HIV)-based vectors have great potential for the therapeutic delivery of genes to cells. We describe here a systematic study of the packaging limit of HIV-based vectors. Restriction endonuclease-generated bacterial chromosomal DNA fragments of different lengths were cloned at three different positions within a lentiviral vector. Vesicular stomatitis virus G protein (VSV G) pseudotyped lentiviral particles were prepared and the different clones were titered on mammalian cells. We observed that the restriction endonuclease site positions at the 5' and 3' ends of the genome were superior with regard to insertional capacity of foreign DNA. In all cases, viral titers decreased semi-logarithmically with increasing vector length. There appears to be no absolute packaging limit because measurable titers were obtained even when the proviral length was in excess of 18 kb. The reduction in titer appears to occur at the level of viral encapsidation, although we cannot exclude limitations in nuclear export of proviral RNA. These results suggest that HIV-based vectors may have a secondary advantage over oncoretroviral vectors because of their greater packaging limit, although the very low titers of the larger vectors will be of limited utility.
Similar articles
-
RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors.Exp Biol Med (Maywood). 2010 Oct;235(10):1269-76. doi: 10.1258/ebm.2010.010053. Epub 2010 Sep 27. Exp Biol Med (Maywood). 2010. PMID: 20876083
-
Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.J Gene Med. 2005 Jun;7(6):818-34. doi: 10.1002/jgm.726. J Gene Med. 2005. PMID: 15693055
-
Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA.Hum Gene Ther. 2000 Sep 20;11(14):2025-37. doi: 10.1089/10430340050143444. Hum Gene Ther. 2000. PMID: 11020801
-
Altering the tropism of lentiviral vectors through pseudotyping.Curr Gene Ther. 2005 Aug;5(4):387-98. doi: 10.2174/1566523054546224. Curr Gene Ther. 2005. PMID: 16101513 Free PMC article. Review.
-
Lentiviral vectors for gene delivery into cells.DNA Cell Biol. 2002 Dec;21(12):937-51. doi: 10.1089/104454902762053873. DNA Cell Biol. 2002. PMID: 12573051 Review.
Cited by
-
CRISPR/Cas9: a tool to eradicate HIV-1.AIDS Res Ther. 2022 Dec 1;19(1):58. doi: 10.1186/s12981-022-00483-y. AIDS Res Ther. 2022. PMID: 36457057 Free PMC article. Review.
-
Unlocking biological mechanisms with integrative functional genomics approaches.Mol Cells. 2024 Aug;47(8):100092. doi: 10.1016/j.mocell.2024.100092. Epub 2024 Jul 15. Mol Cells. 2024. PMID: 39019219 Free PMC article. Review.
-
A non-viral genome editing platform for site-specific insertion of large transgenes.Stem Cell Res Ther. 2020 Sep 3;11(1):380. doi: 10.1186/s13287-020-01890-6. Stem Cell Res Ther. 2020. PMID: 32883366 Free PMC article.
-
The delivery challenge: fulfilling the promise of therapeutic genome editing.Nat Biotechnol. 2020 Jul;38(7):845-855. doi: 10.1038/s41587-020-0565-5. Epub 2020 Jun 29. Nat Biotechnol. 2020. PMID: 32601435 Review.
-
Extending the transposable payload limit of Sleeping Beauty (SB) using the Herpes Simplex Virus (HSV)/SB amplicon-vector platform.Gene Ther. 2010 Mar;17(3):424-31. doi: 10.1038/gt.2009.144. Epub 2009 Oct 29. Gene Ther. 2010. PMID: 19865178 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources